{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:58:17Z","timestamp":1785308297566,"version":"3.55.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ijantimicag.2018.12.014","type":"journal-article","created":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T21:39:45Z","timestamp":1546119585000},"page":"401-407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["The dosing and monitoring of vancomycin: what is the best way forward?"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3367-3335","authenticated-orcid":false,"given":"Philip G.","family":"Drennan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan J.","family":"Begg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon J.","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl M.J.","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve T.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0001","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0002","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/imj.12036","article-title":"Vancomycin therapeutics and monitoring: a contemporary approach","volume":"43","author":"Avent","year":"2013","journal-title":"Intern Med J"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0003","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10156-013-0599-4","article-title":"Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"19","author":"Matsumoto","year":"2013","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0004","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1093\/jac\/dkw254","article-title":"Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society","volume":"71","author":"Ye","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0005","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1128\/AAC.03147-14","article-title":"Optimizing the Clinical Use of Vancomycin","volume":"60","author":"\u00c1lvarez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0006","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/ajhp\/57.suppl_2.S4","article-title":"Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus","volume":"2","author":"Moise","year":"2000","journal-title":"Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm 57 Suppl"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146224","article-title":"Association between the AUC0-24\/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-Analysis","volume":"11","author":"Men","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0008","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are Vancomycin Trough Concentrations Adequate for Optimal Dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0009","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02535-16","article-title":"Establishment of an AUC0-24 Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Bacteremia","volume":"61","author":"Chavada","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0010","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01684-17","article-title":"Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin","volume":"62","author":"Zasowski","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0011","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1128\/AAC.02714-15","article-title":"Vancomycin 24-Hour Area under the Curve\/Minimum Bactericidal Concentration Ratio as a Novel Predictor of Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia","volume":"60","author":"Britt","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0012","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/cid\/cir078","article-title":"Vancomycin: we can't get there from here","volume":"52","author":"Patel","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01293-17","article-title":"The Impact of Vancomycin Area Under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity: a Quasi-Experiment","author":"Finch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0014","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0015","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/647952","article-title":"Antimicrobial Susceptibility Testing: A Review of General Principles and Contemporary Practices","volume":"49","author":"Reller","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0016","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1128\/JCM.00448-13","article-title":"Evaluation of Vancomycin Susceptibility Testing for Methicillin-Resistant Staphylococcus aureus: Comparison of Etest and Three Automated Testing Methods","volume":"51","author":"Rybak","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0017","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1128\/JCM.00957-14","article-title":"Comparison of Commercial Antimicrobial Susceptibility Test Methods for Testing of Staphylococcus aureus and Enterococci against Vancomycin, Daptomycin, and Linezolid","volume":"52","author":"Riedel","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0018","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1128\/AAC.00093-09","article-title":"Nine-Hospital Study Comparing Broth Microdilution and Etest Method Results for Vancomycin and Daptomycin against Methicillin-Resistant Staphylococcus aureus","volume":"53","author":"Sader","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0019","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1128\/AAC.01915-13","article-title":"Activities of Vancomycin, Ceftaroline, and Mupirocin against Staphylococcus aureus Isolates Collected in a 2011 National Surveillance Study in the United States","volume":"58","author":"Richter","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0020","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jac\/dkx427","article-title":"MIC-based dose adjustment: facts and fables","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0021","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1128\/JCM.01571-14","article-title":"Precision of Vancomycin and Daptomycin MICs for Methicillin-Resistant Staphylococcus aureus and Effect of Subculture and Storage","volume":"52","author":"Charlton","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0022","unstructured":"International Organisation for Standardisation. 2007. Clinical laboratory testing and in vitro diagnostic test systems \u2013 Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices \u2013 Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases (ISO 20776-1:2006)."},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0023","unstructured":"EUCAST. Antimicrobial wild type distributions of microorganisms. https:\/\/mic.eucast.org\/Eucast2\/. Last accessed 2018-09-10"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0024","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01663-17","article-title":"Seventy-Five Years of Research on Protein Binding","volume":"62","author":"Dalhoff","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0025","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/106002808802200404","article-title":"Vancomycin serum protein binding determination by ultrafiltration","volume":"22","author":"Ackerman","year":"1988","journal-title":"Drug Intell Clin Pharm"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0026","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1128\/AAC.01674-10","article-title":"Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding","volume":"55","author":"Butterfield","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0027","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/FTD.0000000000000122","article-title":"Measuring unbound versus total vancomycin concentrations in serum and plasma: methodological issues and relevance","volume":"37","author":"Stove","year":"2015","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0028","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.1128\/AAC.01185-15","article-title":"Factors impacting unbound vancomycin concentrations in different patient populations","volume":"59","author":"Oyaert","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0029","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1111\/bcp.13673","article-title":"Total flucloxacillin plasma concentrations poorly reflect unbound concentrations in hospitalized patients with Staphylococcus aureus bacteraemia","volume":"84","author":"Chin","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00280-17","article-title":"Pharmacokinetic Assessment of Vancomycin Loading Dose in Critically Ill Patients","volume":"61","author":"\u00c1lvarez","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0031","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1093\/jac\/dky310","article-title":"Dosing vancomycin in the super obese: less is more","volume":"72","author":"Crass","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0032","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1177\/1060028017750084","article-title":"Vancomycin Dosing in Obese Patients: Special Considerations and Novel Dosing Strategies","volume":"52","author":"Durand","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0033","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/1060028014556813","article-title":"A randomized trial of loading vancomycin in the emergency department","volume":"49","author":"Rosini","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0034","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/acem.12934","article-title":"High Single-dose Vancomycin Loading Is Not Associated With Increased Nephrotoxicity in Emergency Department Sepsis Patients","volume":"23","author":"Rosini","year":"2016","journal-title":"Acad Emerg Med Off J Soc Acad Emerg Med"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0035","doi-asserted-by":"crossref","first-page":"O1098","DOI":"10.1111\/1469-0691.12695","article-title":"Impact of source of infection and vancomycin AUC0\u201324\/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"20","author":"Ghosh","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0036","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1128\/AAC.32.6.848","article-title":"Vancomycin pharmacokinetics in patients with various degrees of renal function","volume":"32","author":"Rodvold","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0037","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cpt1977213362","article-title":"Kinetic model for gentamicin dosing with the use of individual patient parameters","volume":"21","author":"Sawchuk","year":"1977","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0038","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1128\/AAC.01485-12","article-title":"Vancomycin AUC\/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia","volume":"57","author":"Holmes","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0039","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1378\/chest.130.4.947","article-title":"Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices","volume":"130","author":"Jeffres","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0040","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.diagmicrobio.2010.02.026","article-title":"Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"67","author":"Neuner","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0041","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1592\/phco.31.5.441","article-title":"Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg\/L suggested by the vancomycin consensus guidelines","volume":"31","author":"Kullar","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0042","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0043","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00228-016-2063-8","article-title":"Vancomycin dosing nomograms targeting high serum trough levels in different populations: pros and cons","volume":"72","author":"Elyasi","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0044","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/jac\/dkp085","article-title":"Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations","volume":"63","author":"Thomson","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0045","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/phar.1638","article-title":"Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta\u2010analysis of Observational Studies","volume":"35","author":"Prybylski","year":"2015","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0046","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0047","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0048","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40262-012-0020-y","article-title":"Benchmarking therapeutic drug monitoring software: a review of available computer tools","volume":"52","author":"Fuchs","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0049","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4155\/ipk-2018-0005","article-title":"Bayesian therapeutic drug monitoring software: past, present and future","volume":"3","author":"Drennan","year":"2018","journal-title":"Int J Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0050","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1345\/aph.1Q195","article-title":"Evaluation of the accuracy of a pharmacokinetic dosing program in predicting serum vancomycin concentrations in critically ill patients","volume":"45","author":"Aubron","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0051","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1345\/aph.1P634","article-title":"Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software","volume":"45","author":"Nunn","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0052","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02478-16","article-title":"Pilot Study of a Bayesian Approach To Estimate Vancomycin Exposure in Obese Patients with Limited Pharmacokinetic Sampling","volume":"61","author":"Carreno","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0053","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/FTD.0b013e318161a38c","article-title":"Evaluation and Comparison of Simple Multiple Model, Richer Data Multiple Model and Sequential Interacting Multiple Model (IMM) Bayesian Analyses of Gentamicin and Vancomycin Data Collected from Patients Undergoing Cardiothoracic Surgery","volume":"30","author":"Macdonald","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0054","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijantimicag.2015.10.019","article-title":"Continuous versus intermittent infusion of vancomycin in adult patients: A systematic review and meta-analysis","volume":"47","author":"Hao","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.12.014_bib0055","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1128\/AAC.03694-14","article-title":"Influence of Vancomycin Infusion Methods on Endothelial Cell Toxicity","volume":"59","author":"Drouet","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918303844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918303844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T08:33:43Z","timestamp":1662712423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918303844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0924857918303844"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.12.014","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The dosing and monitoring of vancomycin: what is the best way forward?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}